Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary - PubMed (original) (raw)

. 2005 Nov 15;65(22):10602-12.

doi: 10.1158/0008-5472.CAN-05-2240.

Ji-Young Lee, Dong-Choon Park, Mike Radonovich, Cindy Pise-Masison, John Brady, Ginger J Gardner, Ke Hao, Wing H Wong, J Carl Barrett, Karen H Lu, Anil K Sood, David M Gershenson, Samuel C Mok, Michael J Birrer

Affiliations

• PMID: 16288054
• DOI: 10.1158/0008-5472.CAN-05-2240

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary

Tomas Bonome et al. Cancer Res. 2005.

Abstract

Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course. The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined. The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes. Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings. Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations. Unsupervised hierarchical clustering analysis revealed a distinct separation between clusters containing borderline and high-grade lesions. The majority of low-grade tumors clustered with LMP tumors. Comparing OSE with high-grade and LMP expression profiles revealed enhanced expression of genes linked to cell proliferation, chromosomal instability, and epigenetic silencing in high-grade cancers, whereas LMP tumors displayed activated p53 signaling. The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers. Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.

PubMed Disclaimer

Similar articles

• Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
  Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Oncogene. 2005 Feb 3;24(6):1053-65. doi: 10.1038/sj.onc.1208298. Oncogene. 2005. PMID: 15558012
• Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
  McKenney JK, Balzer BL, Longacre TA. McKenney JK, et al. Am J Surg Pathol. 2006 Oct;30(10):1209-21. doi: 10.1097/01.pas.0000213299.11649.fa. Am J Surg Pathol. 2006. PMID: 17001150 Review.
• Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
  May T, Virtanen C, Sharma M, Milea A, Begley H, Rosen B, Murphy KJ, Brown TJ, Shaw PA. May T, et al. Gynecol Oncol. 2010 Apr;117(1):9-17. doi: 10.1016/j.ygyno.2010.01.006. Epub 2010 Feb 1. Gynecol Oncol. 2010. PMID: 20117829
• [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
  Shao HL, Shen DH, Xue WC, Li Y, Yu YZ. Shao HL, et al. Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Zhonghua Fu Chan Ke Za Zhi. 2007. PMID: 17631760 Chinese.
• A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors.
  Kmet LM, Cook LS, Magliocco AM. Kmet LM, et al. Cancer. 2003 Jan 15;97(2):389-404. doi: 10.1002/cncr.11064. Cancer. 2003. PMID: 12518363 Review.

Cited by

• Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.
  Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ. Krzystyniak J, et al. Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i4-i10. doi: 10.1093/annonc/mdw083. Ann Oncol. 2016. PMID: 27141069 Free PMC article. Review.
• AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
  Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ. Rankin EB, et al. Cancer Res. 2010 Oct 1;70(19):7570-9. doi: 10.1158/0008-5472.CAN-10-1267. Epub 2010 Sep 21. Cancer Res. 2010. PMID: 20858715 Free PMC article.
• Low-grade Serous Ovarian Carcinoma.
  Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, Schneider S, du Bois A, Harter P. Ricciardi E, et al. Geburtshilfe Frauenheilkd. 2018 Oct;78(10):972-976. doi: 10.1055/a-0717-5411. Epub 2018 Oct 19. Geburtshilfe Frauenheilkd. 2018. PMID: 30364401 Free PMC article.
• FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer.
  Zhang Q, Yu S, Lok SIS, Wong AST, Jiao Y, Lee LTO. Zhang Q, et al. J Cell Mol Med. 2019 Jul;23(7):4569-4581. doi: 10.1111/jcmm.14360. Epub 2019 Apr 30. J Cell Mol Med. 2019. PMID: 31037837 Free PMC article.
• Genomic analysis of epithelial ovarian cancer.
  Farley J, Ozbun LL, Birrer MJ. Farley J, et al. Cell Res. 2008 May;18(5):538-48. doi: 10.1038/cr.2008.52. Cell Res. 2008. PMID: 18427574 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal